Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: capecitabine

Summary for Generic Name: capecitabine

Drug Master File Entries: see list25
Suppliers: see list3

Pharmacology for Ingredient: capecitabine

Clinical Trials for: capecitabine

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
Status: Recruiting Condition: Breast Neoplasms; Neoplasms by Site; Neoplasm Metastasis; Breast Diseases; Skin Diseases

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; HER2/Neu-positive Breast Cancer

LBH589 in Combination With Capecitabine Plus/Minus (┬▒) Lapatinib in Breast Cancer Patients
Status: Completed Condition: Breast Cancer

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Status: Completed Condition: Advanced Solid Tumors

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Completed Condition: Advanced Solid Tumors; Locally Advanced or Metastatic Breast or Colorectal Cancer

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Status: Terminated Condition: Rectal Cancer

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
Status: Recruiting Condition: Breast Cancer

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
Status: Completed Condition: Metastatic Breast Cancer

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Terminated Condition: Hepatocellular Carcinoma

Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction
Status: Recruiting Condition: Gastric Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mylan Pharms Inc
TABLET;ORAL090943Aug 8, 2014RXNo<disabled>
Teva Pharms Usa
TABLET;ORAL091649Sep 16, 2013RXNo<disabled>
Hoffmann La Roche
TABLET;ORAL020896Apr 30, 1998RXNo5,472,949*PED<disabled>Y
Hoffmann La Roche
TABLET;ORAL020896Apr 30, 1998RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology